An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis.
BACKGROUND
The aim of the study was to compare adalimumab or golimumab with infliximab in patients with moderately-to-severely active ulcerative colitis (UC).


METHODS
This paper was prepared according to the PRISMA guidelines. The systematic literature search was performed in PubMed, Embase, and Cochrane Library. No direct head-to-head comparisons for infliximab vs. adalimumab or golimumab were available so an indirect comparison according to the Bucher method was performed after a homogeneity evaluation of the included studies.


RESULTS
Six RCTs were included in the systematic review. An indirect comparison was performed, which revealed that infliximab was more effective in inducing clinical response compared with both doses of adalimumab (160/80 mg or 80/40 mg;p< 0.05), and, in clinical remission, infliximab was more effective than adalimumab (only for a dosage regime of 80/40 mg;p< 0.05). No statistically significant differences in clinical response and clinical remission were observed between infliximab and golimumab in the induction phase. A significant (p< 0.05) advantage only of infliximab compared with adalimumab at doses of 80/40 mg and 80/160 mg was seen in terms of clinical response in the maintenance phase (up to 52-54 weeks). The indirect comparison revealed that serious adverse events were significantly more frequent among patients treated with a maintenance dose of 100 mg of golimumab compared with those treated with infliximab (p< 0.05).


CONCLUSIONS
No significant differences in efficacy in the maintenance phase between infliximab and golimumab or adalimumab were revealed. Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase.
Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Paweł
P
Kawalec
Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Andrzej
A
Pilc
adalimumab; biological therapy; golimumab; indirect comparison; infliximab; systematic review; ulcerative colitis
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
20068560
Gut. 2003 Jul;52(7):998-1002
12801957
Gut. 2011 Jun;60(6):780-7
21209123
Practitioner. 2013 Jul-Aug;257(1763):13-8, 2
24191430
Gastroenterology. 2014 Jan;146(1):110-118.e3
24067881
Lancet. 2007 May 12;369(9573):1627-40
17499605
Gut. 2006 Nov;55(11):1575-80
16772310
J Gastroenterol Hepatol. 2014 Jun;29(6):1159-70
24955447
Gastroenterol Hepatol (N Y). 2013 Jun;9(6):367-74
23935543
World J Gastroenterol. 2013 Mar 21;19(11):1827-33
23555172
Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5
23735746
Autoimmun Rev. 2004 Jul;3(5):394-400
15288007
Am J Gastroenterol. 2007 Apr;102(4):794-802
17324131
J Pediatr Gastroenterol Nutr. 2009 Apr;48 Suppl 2:S72-4
19300131
N Engl J Med. 2011 Nov 3;365(18):1713-25
22047562
N Engl J Med. 2005 Dec 8;353(23):2462-76
16339095
Gut. 2011 May;60(5):571-607
21464096
J Crohns Colitis. 2008 Jun;2(2):158-61
21172206
Inflamm Bowel Dis. 2012 Feb;18(2):201-11
21484965
Lancet. 2012 Nov 3;380(9853):1606-19
22914296
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112
16856078
Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520
19596014
Aliment Pharmacol Ther. 2013 Jan;37(2):204-13
23173821
Arch Med Sci. 2013 Oct 31;9(5):765-79
24273556
J Crohns Colitis. 2008 Mar;2(1):24-62
21172195
Gastroenterol Hepatol (N Y). 2010 May;6(5):339-46
20567592
Nat Rev Immunol. 2010 May;10(5):301-16
20414204
J Gastroenterol. 2014 Feb;49(2):283-94
24363029
Aliment Pharmacol Ther. 2003 Jul 15;18(2):175-81
12869077
J Clin Epidemiol. 1997 Jun;50(6):683-91
9250266
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
Pharmacol Ther. 2008 Feb;117(2):244-79
18155297
Am J Gastroenterol. 2011 Apr;106(4):644-59, quiz 660
21407183
Aliment Pharmacol Ther. 2010 Oct;32(8):984-9
20937043
Gastroenterology. 2012 Feb;142(2):257-65.e1-3
22062358
Gastroenterology. 2005 Jun;128(7):1805-11
15940615
Ann Surg. 2003 Aug;238(2):229-34
12894016
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
22001864
J Gastroenterol Hepatol. 2012 Aug;27(8):1266-80
22497584
Gastroenterology. 2014 Jan;146(1):96-109.e1
23770005
Ann Intern Med. 2014 May 20;160(10 ):704-11
24842416
N Engl J Med. 2009 Nov 19;361(21):2066-78
19923578
Cytokine. 1995 Apr;7(3):251-9
7640345
PLoS Med. 2009 Jul 21;6(7):e1000097
19621072